Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) is evaluating three potential sites in the United States for its planned integrated iodine and barium contrast drug manufacturing facility, the company announced June 18, 2026. The Canadian developer of pharmaceutical-grade contrast media is conducting a comprehensive analysis of technical, regulatory, economic, and logistical factors to select the optimal location.
The evaluation prioritizes proximity to iodine brine sources, which are expected to support over 70% of future revenue, along with logistics, infrastructure, access to skilled labor, and government incentive packages. Voyageur is actively engaging with economic development authorities across multiple U.S. jurisdictions, with the final site selection depending on the most attractive combination of factors, particularly incentive and support packages. This competitive process aims to optimize project economics and accelerate development timelines.
Strong candidate locations have been identified in Oklahoma and Texas due to their proximity to Voyageur’s iodine extraction initiatives in Oklahoma’s Anadarko Basin, robust transportation infrastructure (rail, highways, and port access), skilled labor availability, abundant municipal water supply, and a competitive business climate with low taxes and cost-effective land and energy. Additionally, these states offer strong local, state, and federal incentives for advanced manufacturing, pharmaceutical and API production, critical minerals processing, and strategic supply chain onshoring.
The pharmaceutical manufacturing facility will receive concentrated iodine liquor from Voyageur’s proprietary closed-loop Streamlined Iodine Process directly from its Oklahoma brine operations, along with high-purity barite from the Frances Creek project. Unlike conventional manufacturers that depend on imported iodine flakes or intermediates and energy-intensive synthetic precipitated barium sulfate, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security for U.S. hospitals, government customers, and international distribution.
Key anticipated project highlights include cost leadership through vertical integration, significant funding and incentive opportunities from U.S. federal and state sources, creation of 150–250 direct high-skilled jobs in manufacturing, engineering, quality assurance, laboratory, and operations, plus substantial indirect jobs through construction and suppliers. Once at full scale, the facility is expected to generate significant annual economic activity, major local tax revenue, and support for regional supply chains. Planned collaboration with post-secondary institutions will establish pharmaceutical training programs and talent pipelines. Centrally located, the facility will serve the North American contrast media market with excellent logistics for domestic and international distribution, while supporting iodine supply for Voyageur’s collaboration with Bayer on the Oklahoma iodine prill project.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other customary conditions. This announcement builds on Voyageur’s ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company continues to work closely with economic development corporations and state/federal partners to advance incentives and permitting. Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring of strategic drugs, and rural economic development.
